Nasu K, Etoh Y, Yoshimatsu J, Matsu T, Narahara H, Miyakawa I
Department of Obstetrics and Gynecology, Oita Medical University, Japan.
Gynecol Obstet Invest. 1996;42(4):267-70. doi: 10.1159/000291978.
Serum levels of a cytokeratin 19 fragment, Cyfra 21-1, were measured using an immunoradiometric assay in 33 women before initial treatment and in 8 women with recurrent tumor. The serum level of Cyfra 21-1 was significantly increased in women with tumors of advanced stage (FIGO) and those with recurrence. The incidence of positivity for Cyfra 21-1 tended to increase with tumor spread. Compared with squamous cell carcinoma (SCC) antigen, the sensitivity of Cyfra 21-1 was comparable to that of SCC antigen. The serum level of Cyfra 21-1 and that of SCC antigen showed a positive correlation. While the use of the serum Cyfra 21-1 level may be limited in cervical cancer by its relatively low sensitivity, a combination assay of Cyfra 21-1 and SCC antigen may be useful in the diagnosis and follow-up of patients with cervical squamous cell carcinoma.
采用免疫放射分析方法测定了33例初治前女性患者及8例复发肿瘤女性患者血清中的细胞角蛋白19片段（Cyfra 21-1）水平。Cyfra 21-1的血清水平在晚期（国际妇产科联盟分期）肿瘤女性患者及复发患者中显著升高。Cyfra 21-1阳性发生率随肿瘤扩散有增加趋势。与鳞状细胞癌（SCC）抗原相比，Cyfra 21-1的敏感性与SCC抗原相当。Cyfra 21-1的血清水平与SCC抗原的血清水平呈正相关。虽然血清Cyfra 21-1水平在宫颈癌中的应用可能因其相对较低的敏感性而受到限制，但Cyfra 21-1与SCC抗原联合检测可能有助于宫颈鳞状细胞癌患者的诊断及随访。
